IGF2BP3 and prostate carcinoma: We demonstrated an association between elevated IGF2BP3 expression and metastasis, as well as a marginal association with adverse disease-specific survival in MCC, which aligns with similar observations in diverse cancer types, including melanoma (Hanniford et al, 2020; Sheen et al, 2015), breast cancer (Jiang et al, 2022), nasopharyngeal carcinoma (Du et al, 2022; Xu et al, 2022), pancreatic cancer (Taniuchi et al, 2014), prostate cancer (Yu et al, 2022), Ewing sarcoma (Mancarella et al, 2020), and bladder cancer (Liu et al, 2022).